干细胞来源外泌体在急性肝衰竭炎症驱动中的应用价值

摘要/Abstract

摘要： 急性肝衰竭(ALF)是由多种肝毒性因素引起的以广泛炎症为特征的严重肝损伤,过度和失控的炎症反应可导致大量肝细胞凋亡、坏死,甚至对肝脏造成不可逆转的损害。ALF的病因多样,病情进展迅速,死亡率高,但内科治疗手段有限。已有研究证实干细胞是一种有潜力的治疗方法,但由于移植后细胞存活率低且有发生恶性转化的风险,因此干细胞的应用同样有限。而干细胞来源外泌体是细胞外囊泡的一个纳米亚群,免疫原性低、生物相容性好、无固有毒性,且具有抗炎、抗凋亡和免疫抑制作用,有可能建立一种更安全、更有效的疗法来修复肝损伤,降低临床死亡率,改善预后。本文就干细胞来源外泌体在急性肝衰竭炎症驱动中的应用价值作一综述。

唐慧昕, 张译之, 陈煜. 干细胞来源外泌体在急性肝衰竭炎症驱动中的应用价值[J]. 肝脏, 2022, 27(1): 8-11.

参考文献

[1] Zhang S, Hou Y, Yang J, et al. Application of mesenchymal stem cell exosomes and their drug-loading systems in acute liver failure. J Cell Mol Med,2020, 24: 7082-7093.
[2] Chamuleau RA, Wlodzimirow KA, Abu-Hanna A. Incorporating dynamics for predicting poor outcome in acute liver failure patients. World J Gastrointest Surg,2012, 4: 281-283.
[3] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版). 西南医科大学学报,2019,42:99-106.
[4] Wang Y, Wang JL, Ma HC, et al. Mesenchymal stem cells increase heme oxygenase 1-activated autophagy in treatment of acute liver failure. Biochem Biophys Res Commun, 2019, 508: 682-689.
[5] Saliba F, Samuel D. Acute liver failure: current trends. J Hepatol,2013, 59: 6-8.
[6] 马臻, 乌云. 肝衰竭的治疗现状. 临床肝胆病杂志,2016, 32: 1668-1672.
[7] Zhang L, Ma XJ, Fei YY, et al. Stem cell therapy in liver regeneration: Focus on mesenchymal stem cells and induced pluripotent stem cells. Pharmacol Ther,2021.
[8] Ferrer JR, Chokechanachaisakul A, Wertheim JA. New Tools in Experimental Cellular Therapy for the Treatment of Liver Diseases. Curr Transplant Rep,2015, 2: 202-210.
[9] Huebert RC, Rakela J. Cellular therapy for liver disease. Mayo Clin Proc, 2014, 89: 414-424.
[10] Taibi F, Metzinger-Le MV, Massy ZA, et al. miR-223: An inflammatory oncomiR enters the cardiovascular field. Biochim Biophys Acta,2014, 1842: 1001-1009.
[11] Li X, Li C, Zhang L, et al. The significance of exosomes in the development and treatment of hepatocellular carcinoma. Mol Cancer,2020, 19: 1.
[12] Burrello J, Monticone S, Gai C, et al. Stem Cell-Derived Extracellular Vesicles and Immune-Modulation. Front Cell Dev Biol,2016, 4: 83.
[13] Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis,2007, 27: 339-350.
[14] Krenkel O, Mossanen JC, Tacke F. Immune mechanisms in acetaminophen-induced acute liver failure. Hepatobiliary Surg Nutr,2014, 3: 331-343.
[15] Filliol A, Piquet-Pellorce C, Le Seyec J, et al. RIPK1 protects from TNF-alpha-mediated liver damage during hepatitis. Cell Death Dis,2016, 7: e2462.
[16] Wu X, Lu Y, Dong Y, et al. The inhalation anesthetic isoflurane increases levels of proinflammatory TNF-alpha, IL-6, and IL-1beta. Neurobiol Aging,2012, 33: 1364-1378.
[17] Cheng CH, Yang FF, Ling RZ, et al. Effects of ammonia exposure on apoptosis, oxidative stress and immune response in pufferfish (Takifugu obscurus). Aquat Toxicol,2015, 164: 61-71.
[18] Zhang D, Tang J, Zhang J, et al. Responses of pro- and anti-inflammatory cytokines in zebrafish liver exposed to sublethal doses of Aphanizomenon flosaquae DC-1 aphantoxins. Aquat Toxicol, 2019, 215: 105269.
[19] Wang J, Ren H, Yuan X, et al. Interleukin-10 secreted by mesenchymal stem cells attenuates acute liver failure through inhibiting pyroptosis. Hepatol Res,2018, 48: E194-E202.
[20] Hu C, Li L. Improvement of mesenchymal stromal cells and their derivatives for treating acute liver failure. J Mol Med (Berl),2019, 97: 1065-1084.
[21] Manakkat VG, Ryan JM, Abeles RD, et al. Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure. Crit Care Med, 2016, 44: 43-53.
[22] Wang YH, Wu DB, Chen B, et al. Progress in mesenchymal stem cell-based therapy for acute liver failure. Stem Cell Res Ther,2018, 9: 227.
[23] Wu HH, Lee OK. Exosomes from mesenchymal stem cells induce the conversion of hepatocytes into progenitor oval cells. Stem Cell Res Ther,2017, 8: 117.
[24] Zhao S, Liu Y, Pu Z. Bone marrow mesenchymal stem cell-derived exosomes attenuate D-GaIN/LPS-induced hepatocyte apoptosis by activating autophagy in vitro. Drug Des Devel Ther,2019,13:2887-2897.
[25] Chen L, Xiang B, Wang X, et al. Exosomes derived from human menstrual blood-derived stem cells alleviate fulminant hepatic failure. Stem Cell Res Ther, 2017, 8: 9.
[26] Jiang L, Zhang S, Hu H, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate acute liver failure by reducing the activity of the NLRP3 inflammasome in macrophages. Biochem Biophys Res Commun, 2019, 508: 735-741.
[27] Yan Y, Jiang W, Tan Y, et al. hucMSC Exosome-Derived GPX1 Is Required for the Recovery of Hepatic Oxidant Injury. Mol Ther, 2017, 25: 465-479.
[28] Wu H, Zhang X, Jia B, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate acetaminophen-induced acute liver failure through activating ERK and IGF-1R/PI3K/AKT signaling pathway. J Pharmacol Sci, 2021, 147: 143-155.
[29] Shao M, Xu Q, Wu Z, et al. Exosomes derived from human umbilical cord mesenchymal stem cells ameliorate IL-6-induced acute liver injury through miR-455-3p. Stem Cell Res Ther, 2020, 11:37.
[30] Tan CY, Lai RC, Wong W, et al. Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther, 2014, 5: 76.
[31] Liu Y, Lou G, Li A, et al. AMSC-derived exosomes alleviate lipopolysaccharide/d-galactosamine-induced acute liver failure by miR-17-mediated reduction of TXNIP/NLRP3 inflammasome activation in macrophages. Ebiomedicine, 2018, 36: 140-150.
[32] Lv H, Fan X, Wang L, et al. Daphnetin alleviates lipopolysaccharide/d-galactosamine-induced acute liver failure via the inhibition of NLRP3, MAPK and NF-kappaB, and the induction of autophagy. Int J Biol Macromol, 2018, 119: 240-248.
[33] Yang X, Yao W, Shi H, et al. Paeoniflorin protects Schwann cells against high glucose induced oxidative injury by activating Nrf2/ARE pathway and inhibiting apoptosis. J Ethnopharmacol, 2016, 185: 361-369.
[34] Zhang Y, Li X, Grailer JJ, et al. Melatonin alleviates acute lung injury through inhibiting the NLRP3 inflammasome. J Pineal Res, 2016, 60: 405-414.
[35] Lai W, Wang J, Huang B, et al. A Novel TNF-α-Targeting Aptamer for TNF-α-Mediated Acute Lung Injury and Acute Liver Failure. Theranostics, 2019, 9: 1741-1751.
[36] Nakamura T, Mizuno S. The discovery of Hepatocyte Growth Factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci,2010,86:588-610.